ClinicalTrials.gg
RecruitingNCT05129605PROGRESSUpdated Nov 10, 2026

Prostate Cancer Genetic Risk Evaluation and Screening Study

An observational study in Prostatic Neoplasm, Prostate Cancer and BRCA2 Mutation, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to male participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Massachusetts General Hospital · Observational

How we know

From the registry’s dates

  • Started Feb 2020; still recruiting 6 years 9 months later.
Updated Nov 10, 2026Eligibility revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
35 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Prostatic Neoplasms by Massachusetts General Hospital — 4 open to participants now, 5 under way, none of them phase 3. Prostatic Neoplasms · Massachusetts General Hospital.

Planned enrollment
3rd of 12
400 · median 55
Started
2020
with 2 others
Observational
12 of 32
3 open now
Registered
29th of 32
by date

Among the 32 studies in Prostatic Neoplasms by Massachusetts General Hospital, this one is the 3rd largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2020, is one of 12 observational ones, and was the 29th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 32 studies in Prostatic Neoplasms by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 35 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Prostatic Neoplasms by Massachusetts General Hospital, or all of them as a file.
02

Study summary

This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.

Read the detailed description

Prostate cancer is the most common malignancy and the second leading cause of cancer-related deaths in American men. Prostate cancer has substantial inherited predisposition and men harboring specific genetic variants or a positive family history have been associated with an increased risk of developing prostate cancer. Men with specific genetic variants, such as pathogenic BRCA2 mutations, are at particularly greater risk of developing aggressive forms of prostate cancer and thus warrant undergoing careful screening for prostate cancer. However, the penetrance of many mutations in prostate cancer risk genes is unknown, and some men have no identifiable mutations in known risk genes despite a strong family history of prostate cancer. Prospectively collected clinical data along with biospecimens from unaffected individuals at high genetic risk for developing prostate cancer will advance the understanding of how specific mutations contribute to the development of prostate cancer and how these prostate cancers might be best detected. The purpose of this study is to prospectively screen men at high risk genetic risk for prostate cancer by prostate exam, PSA, and prostate MRI to characterize the penetrance and cancer-related outcomes of specific mutations, identify potentially novel genetic risk mutations and/or markers for early detection.

03

Conditions studied

  • Prostatic Neoplasm
  • Prostate Cancer
  • BRCA2 Mutation
  • BRCA1 Mutation
  • ATM Gene Mutation
  • MMR Mutation
  • Lynch Syndrome
  • Genetic Predisposition to Disease

Keywords

  • BRCA2
  • BRCA1
  • Mismatch Repair Deficiency
  • Lynch Syndrome
  • HOXB13
  • Family History of Prostate Cancer
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
35 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals aged 35 years or older at high genetic risk for prostate cancer on the basis of a specific germline genetic mutation or a strong family history.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with a prostate aged 35 years or older
  • No known diagnosis of prostate cancer
  • >10 years
  • Meet cohort A, B, or C criteria
  • Cohort A: Documented pathogenic or likely pathogenic germline genetic mutation in a prostate cancer risk gene from a CLIA-certified laboratory (ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53)
  • Cohort B: A strong family history suggestive of high genetic risk for prostate cancer with negative clinical genetic testing
  • Cohort C: Individuals who self-identify as Black American or Black Caribbean with both parents and all four grandparents of Black/African ancestry

Exclusion criteria

Exclusion Criteria:

  • Prior diagnosis or treatment of prostate cancer
  • Inability to undergo prostate MRI
  • Inability to receive MRI contrast agent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort A

    Documented germline known pathogenic or likely pathogenic mutation in a prostate cancer related risk gene

    Diagnostic Test: Prostate cancer screening

  • Cohort B

    Family history suggestive of high genetic risk for prostate cancer with clinical genetic testing negative for known pathogenic or likely pathogenic mutations in prostate cancer-related risk genes

    Diagnostic Test: Prostate cancer screening

  • Cohort C

    Individuals who self-identify as Black American or Black Caribbean with both parents and all four grandparents of Black/African ancestry

    Diagnostic Test: Prostate cancer screening

Interventions

  • Diagnostic testProstate cancer screening

    Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate

06

What researchers measure

Primary outcomes

  1. Diagnosis of prostate cancer

    Diagnosis of overall and clinically significant (grade group 2 or higher) prostate cancer

    Time frame: Up to 10 years

Secondary outcomes

  1. Positive predictive value of multiparametric MRI for detection of prostate cancer

    Positive predictive value of multiparametric prostate MRI for detecting clinically significant prostate cancer in men at high genetic risk for prostate cancer with a positive MRI (PI-RADS score of 3 or higher)

    Time frame: Up to 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Amini AE, Salari K. Incorporating Genetic Risk Into Prostate Cancer Care: Implications for Early Detection and Precision Oncology. JCO Precis Oncol. 2024 Feb;8:e2300560. doi: 10.1200/PO.23.00560. PubMed 38412389 ↗
  • Amini AE, Hunter AE, Almashad A, Feng AJ, Patel ND, O'Dea MR, McCormick SR, Rodgers LH, Salari K. Magnetic Resonance Imaging-based Prostate Cancer Screening in Carriers of Pathogenic Germline Mutations: Interim Results from the Initial Screening Round of the Prostate Cancer Genetic Risk Evaluation and Screening Study. Eur Urol Oncol. 2024 Dec;7(6):1358-1366. doi: 10.1016/j.euo.2024.01.015. Epub 2024 Mar 6. PubMed 38453598 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Dec 2030, 130 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 130 months is above that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2021
First posted
Nov 22, 2021
StartActual
Feb 12, 2020
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2040
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
Maximum age 74 Years→none; 1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore Men 35-74 years oldNow Individuals with a prostate aged 35 years or older
Nov 10, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameDiagnosis of prostate cancerFrom date of enrollment until date of diagnosis of prostate cancer or age of 75 reached, which ever came first → Up to 10 years
Nov 10, 2026
Secondary outcomes
1 time frame changed
What changed in the outcomes
  • Time framePositive predictive value of multiparametric MRI for detection of prostate cancerFrom date of enrollment until date of diagnosis of prostate cancer or age of 75 reached, which ever came first → Up to 10 years
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Eligibility Maximum age 74 Years→none; 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Men 35-74 years oldNow Individuals with a prostate aged 35 years or older
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameDiagnosis of prostate cancerFrom date of enrollment until date of diagnosis of prostate cancer or age of 75 reached, which ever came first → Up to 10 years
    Secondary outcomes 1 time frame changed
    What changed in the outcomes
    • Time framePositive predictive value of multiparametric MRI for detection of prostate cancerFrom date of enrollment until date of diagnosis of prostate cancer or age of 75 reached, which ever came first → Up to 10 years
    + 3 other changes: verification date, oversight details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05129605
Responsible party
Keyan Salari, MD, PhD (Urologic Oncology, Massachusetts General Hospital) — Principal investigator
First posted
Nov 22, 2021
Start date
Feb 12, 2020
Primary completion
Dec 2030 (estimated)
Completion
Dec 2040 (estimated)
Last update
Nov 10, 2026

Study contacts

Olympia Price
Contact
oprice@partners.org
857-238-3838
Keyan Salari, MD, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion